BIOMAT Database Logo BIOMAT Database Logo

Maintenance therapy with recombinant interferon alpha-2B (alpha IFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL). 1996

G Palmieri, and A Morabito, and A Rea, and R Lauria, and V Montesarchio, and E Biondi, and M Caraglia, and P Tagliaferri, and A Bianco

Fifteen patients from a series of 37 consecutive patients with aggressive NHL who achieved a complete remission (CR) with first line chemotherapy were defined at high or high-intermediate risk of relapse according to International Prognostic Risk Index and were treated with alpha IFN as maintenance therapy for two years. After a median follow-up of 62 months only 3/15 patients (20%) relapsed and 2/15 (13.3%) died in the alpha IFN treated group, favourably comparing with the expected relapse and death rate in that setting; on the other hand 40.9% of 'low risk' patients from the same series, who did not receive alpha IFN, had relapsed. alpha IFN maintenance therapy appears to result in prolonged response duration and survival in patients with aggressive and prognostically unfavourable NHL.

UI MeSH Term Description Entries

Related Publications

G Palmieri, and A Morabito, and A Rea, and R Lauria, and V Montesarchio, and E Biondi, and M Caraglia, and P Tagliaferri, and A Bianco
Non-Hodgkin's lymphomas (NHL).
January 1996, Acta oncologica (Stockholm, Sweden),
G Palmieri, and A Morabito, and A Rea, and R Lauria, and V Montesarchio, and E Biondi, and M Caraglia, and P Tagliaferri, and A Bianco
HIV-related non-Hodgkin's lymphoma: CHOP induction therapy and interferon-alpha-2b/zidovudine maintenance therapy.
March 1998, Leukemia & lymphoma,
G Palmieri, and A Morabito, and A Rea, and R Lauria, and V Montesarchio, and E Biondi, and M Caraglia, and P Tagliaferri, and A Bianco
Maintenance therapy with interferon alfa 2b in Hodgkin's disease.
August 1998, Leukemia & lymphoma,
G Palmieri, and A Morabito, and A Rea, and R Lauria, and V Montesarchio, and E Biondi, and M Caraglia, and P Tagliaferri, and A Bianco
Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids.
August 1992, European journal of haematology,
G Palmieri, and A Morabito, and A Rea, and R Lauria, and V Montesarchio, and E Biondi, and M Caraglia, and P Tagliaferri, and A Bianco
[Malignant lymphomas. Non-Hodgkin's lymphomas (NHL). I].
March 1980, Minerva medica,
G Palmieri, and A Morabito, and A Rea, and R Lauria, and V Montesarchio, and E Biondi, and M Caraglia, and P Tagliaferri, and A Bianco
Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
September 1989, Journal of interferon research,
G Palmieri, and A Morabito, and A Rea, and R Lauria, and V Montesarchio, and E Biondi, and M Caraglia, and P Tagliaferri, and A Bianco
Recombinant human interferon alpha-2b (rh IFN alpha-2b) therapy for steroid resistant idiopathic thrombocytopenic purpura (ITP).
January 1996, American journal of hematology,
G Palmieri, and A Morabito, and A Rea, and R Lauria, and V Montesarchio, and E Biondi, and M Caraglia, and P Tagliaferri, and A Bianco
Leucocyte-derived interferon-alpha in patients with antibodies to recombinant IFN-alpha 2b.
April 1988, Lancet (London, England),
G Palmieri, and A Morabito, and A Rea, and R Lauria, and V Montesarchio, and E Biondi, and M Caraglia, and P Tagliaferri, and A Bianco
Maintenance therapy with interferon-alpha 2b, cyclophosphamide, and prednisone in aggressive diffuse large cell lymphoma.
April 2004, Stem cells and development,
G Palmieri, and A Morabito, and A Rea, and R Lauria, and V Montesarchio, and E Biondi, and M Caraglia, and P Tagliaferri, and A Bianco
Combination chemotherapy of unfavourable prognosis non-Hodgkin's lymphomas (NHL). A retrospective study of 53 cases.
December 1981, Haematologica,
Copied contents to your clipboard!